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Impact of New American Thoracic Society Diagnostic
Criteria on Management of Nontuberculous
Mycobacterial Infection
To the Editor:
TheAmerican Thoracic Society has recently published new diag-
nostic criteria for nontuberculousmycobacterial (NTM) diseases
(1). We retrospectively assessed the impact of the new criteria
on clinical practice by reviewing medical ﬁles of all patients in
whom Mycobacterium chelonae, M. abscessus, M. simiae, or M.
szulgai were isolated between January 1999 and January 2005 in
The Netherlands. Isolates were earlier identiﬁed at the National
Mycobacteria Reference Laboratory (RIVM), by either reverse
line blot assay (InnoLipa Mycobacteria v2; Innogenetics, Ghent,
Belgium) or 16S gene sequencing, or by a self-sufﬁcient hospital
laboratory. Approximately 7.7% (9/117) more pulmonary pa-
tients met the 2007 diagnostic criteria (1) than the 1997 criteria
(2), although this differed by NTM species (Table 1).
TABLE 1. FULFILLMENT OF THE DIAGNOSTIC CRITERIA,
BY SPECIES AND SITE
Age 1997 ATS, 2007 ATS,
Species Site n (yr) n (% ) n (% )
Mycobacterium
chelonae P 35 57 5 (14) 7 (20)
EP 11 51 8 (73) 7 (64)
M. abscessus P 39 51 11 (28) 13 (33)
EP 10 52 9 (90) 9 (90)
M. szulgai P 15 60 8 (53) 11 (73)
EP 6 44 6 (100) 5 (83)
M. simiae P 28 65 6 (21) 8 (29)
Definition of abbreviations: Agemean age; ATS American Thoracic Society
diagnostic criteria met; EP  extrapulmonary isolates; P  pulmonary isolates.
The new diagnostic criteria contain more speciﬁc radiological
criteria, whereas bacteriological criteria have become more le-
nient: a single NTM culture from bronchial washing ﬂuid, in a
well-deﬁned class of patients, or two positive sputum cultures
now sufﬁce to establish the diagnosis. As more patients are likely
to meet the new criteria, more patients might receive antimyco-
bacterial treatment. The authors, however, repeatedly state that
meeting these criteria does not, per se, necessitate the institution
of therapy (1). This was not emphasized in the former statement.
We believe such comments only add to the confusion for the
clinician. Which factors should inﬂuence this treatment decision
in individual patients? Ten years of experience with the former
criteria apparently have not provided the answer to that ques-
tion. More lenient criteria even increase the responsibility of
physicians in the treatment decision.
Increased exposure to antimycobacterial drugs can harm pa-
tients, both in terms of adverse events and cost (3). The variable
cure rates achievable per type of NTMdisease and persistence of
the conditions predisposing to NTM infection further complicate
the assessment of the beneﬁt of treatment. Centralization of
expertise and easily accessible expert consultation are important,
as acknowledged in the new statement. For extrapulmonary
NTM isolates, no criteria for additional proof of infection are
mentioned in the summarized criteria, contrary to the prior state-
ment (2). This complicates assessment of the signiﬁcance of
NTM isolated from pleural ﬂuid, stool, or gastric juice, without a
context of disseminated disease, and in theHIV-negative patient,
without histological proof of infection (Table 1). More research
is needed to improve diagnosis and treatment of this increasing
problem in clinical practice.
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